Track H. Lundbeck A/S — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

H. Lundbeck A/S LUN.CO · Stock Open H. Lundbeck A/S in new tab

172.70 DKK
Yield
2.61%
Safety Score
92
Loading chart...
Dividend
Dividend Yield2.61%
Annual dividends1.15 DKK
Ex-Div. DateMarch 24, 2022
Payout29.41%

DCF Valuation

Tweak assumptions to recompute fair value for H. Lundbeck A/S (LUN.CO)
Currency: DKK
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

H. Lundbeck A/S Logo H. Lundbeck A/S Analysis (LUN.CO)

Denmark Health Care Official Website Stock

Is H. Lundbeck A/S a good investment? H. Lundbeck A/S (LUN.CO) is currently trading at 172.70 DKK.

For income investors, H. Lundbeck A/S pays a dividend yield of 2.61%. With a payout ratio of 29%, the dividend appears sustainable.

Investor FAQ

Does H. Lundbeck A/S pay a dividend?

Yes, it pays an annual dividend of 1.15 DKK (2.61% yield).

What asset class is H. Lundbeck A/S?

H. Lundbeck A/S is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Exchange Ticker
CPH (Denmark) LUN.CO
Trades
Dividend Yield
2.61%
Annual Dividends
1.15DKK
Next Ex. Div Date
March 24, 2022
Payout Ratio
29.41%
Dividend History paid per year (DKK)
Historical Dividends
Year Total Dividends
▸2022
2.00 DKK
March 24, 2022 2.0000
▸2021
2.50 DKK
March 24, 2021 2.5000
▸2020
4.10 DKK
March 25, 2020 4.1000
▸2019
12.00 DKK
March 27, 2019 12.0000
▸2018
8.00 DKK
March 21, 2018 8.0000
▸2017
2.45 DKK
March 31, 2017 2.4500
▸2014
2.77 DKK
March 27, 2014 2.7700
▸2013
2.00 DKK
March 22, 2013 2.0000
▸2012
6.98 DKK
March 30, 2012 3.4900
March 22, 2012 3.4900
▸2011
3.77 DKK
March 31, 2011 3.7700
▸2010
3.07 DKK
April 21, 2010 3.0700
▸2009
2.30 DKK
April 22, 2009 2.3000
▸2008
2.56 DKK
April 23, 2008 2.5600
▸2007
1.57 DKK
April 25, 2007 1.5700
▸2006
2.10 DKK
April 25, 2006 2.1000
▸2005
2.21 DKK
April 15, 2005 2.2100
▸2004
1.77 DKK
March 31, 2004 1.7700
▸2002
1.14 DKK
April 10, 2002 1.1400
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion